Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03940352
Recruitment Status : Recruiting
First Posted : May 7, 2019
Last Update Posted : August 20, 2019
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:

This is a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or venetoclax in subjects with AML or high-risk MDS.

For all subjects, TP53wt status must be characterized by, at a minimum, no mutations noted in exons 5, 6, 7 and 8.

Two treatment arms will enroll subjects in parallel to characterize the safety, tolerability, PK, PD and preliminary antitumor activity of HDM201+MBG453 (treatment arm 1) and HDM201+venetoclax (treatment arm 2).

  • In the treatment arm 1, subjects will receive HDM201 in combination with MBG453.
  • In the treatment arm 2, subjects will receive HDM201 in combination with venetoclax. Venetoclax dose will be gradually increased (ramp-up) over a period of 4 to 5 days to achieve the daily target dose tested that will be subsequently continued.

Upon the completion of the escalation part, MTD(s) and/or RD(s) of HDM201 in combination with MBG453 or venetoclax in AML and high-risk MDS subjects will be determined for each treatment arm.


Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia (AML) High-risk Myelodysplastic Syndrome (MDS) Drug: HDM201 Biological: MBG453 Drug: Venetoclax Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Actual Study Start Date : June 24, 2019
Estimated Primary Completion Date : April 22, 2021
Estimated Study Completion Date : April 22, 2021


Arm Intervention/treatment
Experimental: treatment arm1: HDM201+MBG453
Phase Ib (escalation)
Drug: HDM201
Capsule

Biological: MBG453
LIVI (Liquid in vial) Concentrate for Solution for infusion

Experimental: treatment arm2: HDM201+venetoclax
Phase Ib (escalation)
Drug: HDM201
Capsule

Drug: Venetoclax
Tablet




Primary Outcome Measures :
  1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety [ Time Frame: at month 24 ]
    Month 24 is assumed to be study end

  2. Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety [ Time Frame: at month 24 ]
    Month 24 is assumed to be study end

  3. Incidence of dose limiting toxicities (DLTs) of treatment [ Time Frame: at day 28 ]
    end of first cycle

  4. Frequency of dose interuptions [ Time Frame: at month 24 ]
    Month 24 is assumed to be study end

  5. Frequency of dose reductions [ Time Frame: at month 24 ]
    Month 24 is assumed to be study end

  6. Dose intensities [ Time Frame: at month 24 ]
    measured in mg/ day Month 24 is assumed to be study end


Secondary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: at month 24 ]
    Month 24 is assumed to be study end

  2. Best Overall Response (BOR) [ Time Frame: at month 24 ]
    Month 24 is assumed to be study end

  3. Event Free Survival (EFS) for AML (Cheson 2003) or Progression Free Survival (PFS) for MDS (Cheson 2006) [ Time Frame: at month 24 ]
    Month 24 is assumed to be study end

  4. Relapse Free Survival (RFS) for AML (Cheson 2003) or Time To Response (TTR) for MDS (Cheson 2006) [ Time Frame: at month 24 ]
    Month 24 is assumed to be study end

  5. Duration Of Response (DOR) for AML (Cheson 2003) and MDS (Cheson 2006) [ Time Frame: at month 24 ]
    Month 24 is assumed to be study end

  6. Presence of anti-MBG453 antibodies (treatment arm 1 HD201+MBG453) [ Time Frame: at Day 1, Day 29 and at month 24 ]
  7. Concentration of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) [ Time Frame: at Day 1, Day 2, Day 5, Day 6 and Day 29 ]
  8. Concentration of MBG453 (treatment arm 1 HDM201+MBG453) [ Time Frame: at Day 1, Day 2, Day 8, Day 11, Day 15, Day 29 and at month 24 ]
  9. Concentration of venetoclax (treatment arm 2 HDM201+venetoclax) [ Time Frame: at Day 1, Day 2, Day 3, Day 5, Day 6, Day 8, Day 9, Day 14, Day 15 and Day 29 ]
  10. PK parameter (AUC) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) [ Time Frame: at month 6 ]
    Cycle 6

  11. PK parameter (Cmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) [ Time Frame: at month 6 ]
    Cycle 6

  12. PK parameter (Tmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) [ Time Frame: at month 6 ]
    Cycle 6

  13. PK parameter (AUC) of MBG453 (treatment arm 1 HDM201+MBG453) [ Time Frame: at month 6 ]
    Cycle 6

  14. PK parameter (Cmax) of MBG453 (treatment arm 1 HDM201+MBG453) [ Time Frame: at month 6 ]
    Cycle 6

  15. PK parameter (Tmax) of MBG453 (treatment arm 1 HDM201+MBG453) [ Time Frame: at month 6 ]
    Cycle 6

  16. PK parameter (AUC) of venetoclax (treatment arm 2 HDM201+venetoclax) [ Time Frame: at month 6 ]
    Cycle 6

  17. PK parameter (Cmax) of venetoclax (treatment arm 2 HDM201+venetoclax) [ Time Frame: at month 6 ]
    Cycle 6

  18. PK parameter (Tmax) of venetoclax (treatment arm 2 HDM201+venetoclax) [ Time Frame: at month 6 ]
    Cycle 6

  19. Changes from baseline in GDF-15 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) [ Time Frame: at Day 1 and Day 2 ]
  20. Changes from baseline in soluble TIM-3 (Treatment arm 1 HDM201+MBG453) [ Time Frame: at month 6 ]
    Cycle 6



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  • Male or female patients ≥ 18 years of age at the date of ICF signature who present with one of the following:

    1. Relapsed/refractory AML following ≥1 prior therapies (but ≤3 prior therapies) who have relapsed or exhibited refractory disease (primary failure) and are deemed by the Investigator not to be candidates for standard therapy, including re-induction with cytarabine or other established chemotherapy regimens for patients with AML (patients who are suitable for standard re-induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded)
    2. First line AML patient unfit for standard induction chemotherapy (includes both de novo and secondary AML), except in countries where approved therapies are available. Patients who are suitable for hematopoietic stem cell transplantation and willing to receive it are excluded.
    3. High-risk MDS patient (high and very high-risk groups according to rIPSS) who have failed hypomethylating agent therapy.
  • ECOG performance status ≤ 1
  • TP53wt tumor. At minimum exons 5, 6, 7 and 8 in the TP53 gene must be sequenced and determined to contain no mutations. The TP53 status must be obtained from a bone-marrow sample, collected no longer than 3 months before signing the main ICF.
  • Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to the institutional guidelines and be willing to undergo a bone marrow aspirate and/or biopsy at screening, during and at the end of therapy on this study. Exceptions may be considered after documented discussion with Novartis.

Main Exclusion Criteria:

Patients eligible for this study must not meet any of the following criteria:

  • Prior combination treatment with compounds having the same mode of action:

    • mdm2 or mdm4 inhibitors combined with TIM-3 inhibitors (for patients enrolled in treatment arm1)
    • mdm2 or mdm4 inhibitors combined with Bcl-2 inhibitor (for patients enrolled in treatment arm2)
  • History of severe hypersensitivity reactions to any ingredient of study drug(s) and other monoclonal antibodies (mAbs) and/or their excipients.
  • Patients with acute promyelocytic leukemia with PML-RARA.
  • Allogeneic stem cell transplant (HSCT) within last 6 months and/or active GvHD requiring systemic immunosuppressive therapy.
  • GI disorders impacting absorption of oral HDM201 or venetoclax.
  • Evidence of active bleeding or bleeding diathesis or major coagulopathy (including familial).
  • Patients with active, known or suspected autoimmune disease (treatment arm 1 only).

Other eligibility criteria apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03940352


Contacts
Layout table for location contacts
Contact: Novartis Pharmaceuticals 1-888-669-6682 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals +41613241111

Locations
Layout table for location information
Australia, Victoria
Novartis Investigative Site Recruiting
Melbourne, Victoria, Australia, 3004
Finland
Novartis Investigative Site Recruiting
Helsinki, Finland, FIN 00290
Singapore
Novartis Investigative Site Recruiting
Singapore, Singapore, 119228
Sponsors and Collaborators
Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03940352     History of Changes
Other Study ID Numbers: CHDM201H12101C
2018-004001-62 ( EudraCT Number )
First Posted: May 7, 2019    Key Record Dates
Last Update Posted: August 20, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Phase Ib
BHLRM
AML
MDS
HDM201
TP53
MBG453
TIM-3
venetoclax
Bcl-2
Additional relevant MeSH terms:
Layout table for MeSH terms
Venetoclax
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Preleukemia
Myelodysplastic Syndromes
Syndrome
Disease
Pathologic Processes
Neoplasms by Histologic Type
Neoplasms
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Antineoplastic Agents